Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN -Amplified Neuroblastoma In Vivo

1 Sept 2011

Abstract excerpt

Aurora kinases regulate key stages of mitosis including centrosome maturation, spindle assembly, chromosome segregation, and cytokinesis. Aurora A and B kinase overexpression has also been associated with various human cancers, and as such, they have been extensively studied as novel antimitotic drug targets. Here, we characterize the Aurora kinase inhibitor CCT137690, a highly selective, orally bioavailable...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cellular transport and secretion
Share to Microtubule and mitosis dynamics
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21885865
DOI: 10.1158/1535-7163.mct-11-0333

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN -Amplified Neuroblastoma In VivoPMID 21885865Read ↗

TAS-119, a novel selective Aurora A and TRK inhibitor, exhibits antitumor efficacy in preclinical models with deregulated activation of the Myc, β-Catenin, and TRK pathways.Semantic proximity Read ↗

Aurora B kinase is a potent and selective target in MYCN-driven neuroblastomaSemantic proximity Read ↗

Preclinical evaluation of AMG 900, a novel potent and highly selective pan-aurora kinase inhibitor with activity in taxane-resistant tumor cell lines.Semantic proximity Read ↗

Aurora Kinase Inhibitors - Rising Stars in Cancer Therapeutics?Semantic proximity Read ↗

Aurora A–Selective Inhibitor LY3295668 Leads to Dominant Mitotic Arrest, Apoptosis in Cancer Cells, and Shows Potent Preclinical Antitumor EfficacySemantic proximity Read ↗

Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase InhibitorSemantic proximity Read ↗

Aurora Kinases as Targets in Drug-Resistant Neuroblastoma CellsSemantic proximity Read ↗

MYCN sensitizes human neuroblastoma to apoptosis by HIPK2 activation through a DNA damage response.Semantic proximity Read ↗

SUV39H1 epigenetically modulates the MCPIP1-AURKA signaling axis to enhance neuroblastoma tumorigenesisSemantic proximity Read ↗

Aurora kinase inhibitors as anti-cancer therapySemantic proximity Read ↗

Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancerSemantic proximity Read ↗

Aurora Kinases: New Targets for Cancer TherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.